1-4 of 4
Andrew Protheroe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT175: Neoadjuvant olaparib and cediranib in renal cancer: Outcomes of the WIndow-of-opportunity in REnal cancer (WIRE) Trial

Free
James O. Jones, Ines Horvat Menih, Martin Thomas, Helen Mossop, Rebecca Wray, Maria Aquino, James Armitage, Harriet Baker, Carley Batley, James Blackmur, Sarah Burge, Anita Chhabra, Farhana Easita, Tim Eisen, Kate Fife, Angela Godoy, Richard Goodwin, Will Ince, Rose John, Alexander Laird, Natalia Lukashchuk, Athena Matakidou, Thomas J. Mitchell, Andrew N. Priest, Andrew Protheroe, Sreenidhi Ranjit, Anthony Riddick, Sulekha Said, Jamal Sipple, Amy Strong, Helen Su, Mark Sullivan, Silvia Tarantino, Gemma Tsang-Pells, Stephan Ursprung, Balaji Venugopal, Lauren Wallis, Anne Y. Warren, James Wason, Sarah J. Welsh, Younghwa Kim, John Stone, Mireia Crispin-Ortuzar, Ferdia A. Gallagher, Brent O'Carrigan, Grant D. Stewart
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT175.
https://doi.org/10.1158/1538-7445.AM2025-CT175
Published: 25 April 2025
View articletitled, Abstract CT175: Neoadjuvant olaparib and cediranib in renal cancer: Outcomes of the WIndow-of-opportunity in REnal cancer (WIRE) Trial
Journal Articles

Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response

Available to Purchase
Ping Zhang, Isaac Kitchen-Smith, Lingyun Xiong, Giovanni Stracquadanio, Katherine Brown, Philipp H. Richter, Marsha D. Wallace, Elisabeth Bond, Natasha Sahgal, Samantha Moore, Svanhild Nornes, Sarah De Val, Mirvat Surakhy, David Sims, Xuting Wang, Douglas A. Bell, Jorge Zeron-Medina, Yanyan Jiang, Anderson J. Ryan, Joanna L. Selfe, Janet Shipley, Siddhartha Kar, Paul D. Pharoah, Chey Loveday, Rick Jansen, Lukasz F. Grochola, Claire Palles, Andrew Protheroe, Val Millar, Daniel V. Ebner, Meghana Pagadala, Sarah P. Blagden, Timothy S. Maughan, Enric Domingo, Ian Tomlinson, Clare Turnbull, Hannah Carter, Gareth L. Bond
Journal: Cancer Research
Cancer Res (2021) 81 (7): 1667–1680.
https://doi.org/10.1158/0008-5472.CAN-20-0177
Published: 01 April 2021
View articletitled, Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response
Open the PDF for Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response in another window
Includes: Supplementary data
Journal Articles

Abstract 3593: Raptor upregulation contributes to maintenance of 4EBP1 phosphorylation and TORC kinase resistance in renal cancer cells

Free
Philip Earwaker, Frances Willenbrock, Andrew Protheroe, Valentine Macaulay
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3593.
https://doi.org/10.1158/1538-7445.AM2015-3593
Published: 01 August 2015
View articletitled, Abstract 3593: Raptor upregulation contributes to maintenance of 4EBP1 phosphorylation and TORC kinase resistance in renal cancer cells
Journal Articles

Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer

Free
Joaquin Mateo, Shahneen Sandhu, Susana Miranda, Suzanne Carreira, Suneil Jain, Christy Ralph, Andrew Protheroe, Syed Hussain, Robert Jones, Tony Elliot, Ursula McGovern, Alexa Gillman, Claire Paulding, Helen Mossop, Nuria Porta, Diletta Bianchini, Zafeiris Zafeiriou, Gunther Boysen, Daniel Nava Rodrigues, Penelope Flohr, George Seed, Jane Goodall, Ines Figueiredo, Raquel Perez-Lopez, Nina Tunariu, Aurelius Omlin, Roberta Ferraldeschi, Lakshmi P. Kunju, Rosalind Eeles, Gerhardt Attard, Dan Robinson, Arul Chinnaiyan, Emma Hall, Johann S. de Bono
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): CT322.
https://doi.org/10.1158/1538-7445.AM2015-CT322
Published: 01 August 2015
View articletitled, Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer